Linked Life Data

19470735

Source:http://linkedlifedata.com/resource/pubmed/id/19470735

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2009-6-2
pubmed:abstractText
Inhibition of tumor angiogenesis emerged as valuable strategy to treat cancer and has revolutionized the face of clinical oncology by prolonging the life of numerous cancer patients. However, the duration of this response is rather short and tumors rapidly evade treatment, leaving antiangiogenic treatment thus far unable to cure cancer. Hence, novel targets are needed to diversify antiangiogenic treatments and to overcome resistance. Recent data support the concept that tumor infiltration by bone marrow-derived myeloid cells confers resistance to current antiangiogenic drugs targeting primarily vascular endothelial growth factor (VEGF). In this review, we will summarize (pre)clinical data on the role of PlGF and its receptor VEGFR-1 in promoting angiogenesis and inflammation, and the "antimyeloangiogenic" activity of an antibody against PlGF (alphaPlGF), which may help to overcome resistance against VEGF(R)Is. Because of these promising results, a humanized alphaPlGF antibody (TB403) is currently evaluated in different phase I clinical trials in cancer patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3648-53
pubmed:dateRevised
2009-11-25
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
pubmed:affiliation
Vesalius Research Center (VRC), VIB, Katholieke Universiteit Leuven, Leuven, Belgium.
pubmed:publicationType
Journal Article, Review